


Linperlisib

Cat. No.:	HY-102031		
CAS No.:	1702816-75-8		
Molecular Formula:	C ₂₈ H ₃₇ FN ₆ O ₅ S		
Molecular Weight:	588.69		
Target:	PI3K		
Pathway:	PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (169.87 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.6987 mL	8.4934 mL	16.9869 mL
	5 mM	0.3397 mL	1.6987 mL	3.3974 mL
	10 mM	0.1699 mL	0.8493 mL	1.6987 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC₅₀ of 6.4 nM^[1].

IC₅₀ & Target

PI3Kδ
6.4 nM (IC₅₀)

In Vitro

Linperlisib (YY-20394) is under the study for the recurrent and/or refractory follicular lymphoma.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. WO 2015055071 A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA